Načítá se...
MON-365 Immune Checkpoint Inhibitors: Endocrinopathies and Severe Electrolyte Abnormalities
Background: Immune Checkpoint Inhibitors (ICPi) are promising therapies for advanced malignancies, including melanoma, lung cancer, and renal cancer. However, their use can induce mechanism-based toxicities called as immune-related adverse events (irAE) that can potentially affect various organ tiss...
Uloženo v:
| Vydáno v: | J Endocr Soc |
|---|---|
| Hlavní autoři: | , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Endocrine Society
2019
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6550888/ https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1210/js.2019-MON-365 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|